The efficacy and safety of the Gefapixant in patients with interstitial lung disease

A prospective observational study on the efficacy and safety of the Gefapixant in patients with interstitial lung disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031220275

Enrollment

Registered

2022-08-17

Start date

2022-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with interstitial lung disease Patients who have been fully informed of the study and given the consent More than 18 years old patients

Exclusion criteria

Exclusion criteria: Patients unable to give the consent Patients allergic to sulfonamide group Other patients deemed unsuitable for the study by the principal investigator or the sub-investigator Patients already taking gefapixant

Design outcomes

Primary

Measure	Time frame
The change of the Japanese Leicester Cough Questionnaire score at 28 days.	—

Secondary

Measure	Time frame
The change of the cough severity visual analog scale and the COPD assessment test score at 28 days All adverse events Taste-related serious adverse events included ageusia, dysgeusia, hypergeusia, hypogeusia, and taste disorder	—

Contacts

Public ContactMitsuhiro Abe

Chiba University Hospital

mthrsgnm@chiba-u.jp+81-43-222-7171

Outcome results